Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women

Antiviral Research

Volumn 81, Issue 2, 2009, Pages 103-112

  Nazli, Aisha ^a   Yao, Xiao Dan ^a   Smieja, Marek ^a   Rosenthal, Kenneth L ^a   Ashkar, Ali A ^a   Kaushic, Charu ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti viral responses; HSV 2; Human genital epithelium; Innate immunity; Sexually transmitted virus; TLR ligands

Indexed keywords

BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MICROBICIDE; NITRIC OXIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOMETRIUM CELL; EPITHELIUM CELL; GENE EXPRESSION; GENITAL EPITHELIUM CELL; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INNATE IMMUNITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX EPITHELIUM; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; CELLS, CULTURED; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HERPESVIRUS 2, HUMAN; HUMANS; INTERFERON-BETA; MIDDLE AGED; NITRIC OXIDE; TOLL-LIKE RECEPTORS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 2;

EID: 58249086367     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.10.005     Document Type: Article

References (45)

1. Abbo L., Vincek V., Dickinson G., Shrestha N., Doblecki S., and Haslett P.A. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital Herpes simplex vegetans treated with imiquimod. Clin. Infect. Dis. 44 (2007) e25-e27
2. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
3. Andersen J.M., Al-Khairy D., and Ingalls R.R. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol. Reprod. 74 (2006) 824-831
4. Ashkar A.A., Bauer S., Mitchell W.J., Vieira J., and Rosenthal K.L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of Herpes simplex virus type 2. J. Virol. 77 (2003) 8948-8956
5. Ashkar A.A., Yao X.D., Gill N., Sajic D., Patrick A.J., and Rosenthal K.L. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190 (2004) 1841-1849
6. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 (2007) 787-797
7. Barton G.M., and Medzhitov R. Toll-like receptor signaling pathways. Science 300 (2003) 1524-1525
8. Boivin N., Sergerie Y., Rivest S., and Boivin G. Effect of pretreatment with toll-like receptor agonists in a mouse model of Herpes simplex virus type 1 encephalitis. J. Infect. Dis. 198 (2008) 664-672
9. Bussiere F.I., Chaturvedi R., Cheng Y., Gobert A.P., Asim M., Blumberg D.R., Xu H., Kim P.Y., Hacker A., Casero Jr. R.A., and Wilson K.T. Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation. J. Biol. Chem. 280 (2005) 2409-2412
10. Colasanti M., and Suzuki H. The dual personality of NO. Trends Pharmacol. Sci. 21 (2000) 249-252
11. Corey L., Adams H.G., Brown Z.A., and Holmes K.K. Genital Herpes simplex virus infections: clinical manifestations, course, and complications. Ann. Intern. Med. 98 (1983) 958-972
12. Corey L., Bodsworth N., Mindel A., Patel R., Schacker T., and Stanberry L. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 14 Suppl. 1 (2007) 5A-11A
13. Corey L., and Wald A. Genital herpes. In: Holmes K.K., Mardh P.A., Lemon S.A., et al. (Eds). Sexually Transmitted Diseases. third ed. (1999), McGraw-Hill, New York 285-312
14. Elco C.P., Guenther J.M., Williams B.R., and Sen G.C. Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-kappaB, and interferon but not toll-like receptor 3. J. Virol. 79 (2005) 3920-3929
15. Fernandez S., Gillgrass A., and Kaushic C. Differential responses of murine vaginal and uterine epithelial cells prior to and following Herpes simplex virus type 2 (HSV-2) infection. Am. J. Reprod. Immunol. 57 (2007) 367-377
16. Fichorova R.N., Cronin A.O., Lien E., Anderson D.J., and Ingalls R.R. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of Toll-like receptor 4-mediated signaling. J. Immunol. 168 (2002) 2424-2432
17. Fox-Canale A.M., Hope T.J., Martinson J., Lurain J.R., Rademaker A.W., Bremer J.W., Landay A., Spear G.T., and Lurain N.S. Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 369 (2007) 55-68
18. Gill N., Deacon P.M., Lichty B., Mossman K.L., and Ashkar A.A. Induction of innate immunity against Herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J. Virol. 80 (2006) 9943-9950
19. Gursel M., Verthelyi D., Gursel I., Ishii K.J., and Klinman D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukoc. Biol. 71 (2002) 813-820
20. Haddow L.J., and Mindel A. Genital herpes vaccines-cause for cautious optimism. Sex. Health 3 (2006) 1-4
21. Harandi A.M., Eriksson K., and Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77 (2003) 953-962
22. Hartmann G., and Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164 (2000) 944-953
23. Herbst-Kralovetz M., and Pyles R. Toll-like receptors, innate immunity and HSV pathogenesis. Herpes 13 (2006) 37-41
24. Herbst-Kralovetz M.M., and Pyles R.B. Quantification of poly(I:C)-mediated protection against genital Herpes simplex virus type 2 infection. J. Virol. 80 (2006) 9988-9997
25. Herbst-Kralovetz M.M., Quayle A.J., Ficarra M., Greene S., Rose II W.A., Chesson R., Spagnuolo R.A., and Pyles R.B. Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am. J. Reprod. Immunol. 59 (2008) 212-224
26. Hillier S.L., Moench T., Shattock R., Black R., Reichelderfer P., and Veronese F. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 39 (2005) 1-8
27. Kawai T., and Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. (2007)
28. Kawai T., and Akira S. TLR signaling. Semin. Immunol. 19 (2007) 24-32
29. Kedzierska K., Crowe S.M., Turville S., and Cunningham A.L. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev. Med. Virol. 13 (2003) 39-56
30. Koelle D.M. Vaccines for Herpes simplex virus infections. Curr. Opin. Invest. Drugs 7 (2006) 136-141
31. Lauzon N.M., Mian F., MacKenzie R., and Ashkar A.A. The direct effects of Toll- like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell. Immunol. 241 (2006) 102-112
32. Macdonald E.M., Savoy A., Gillgrass A., Fernandez S., Smieja M., Rosenthal K.L., Ashkar A.A., and Kaushic C. Susceptibility of human female primary genital epithelial cells to Herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection. Biol. Reprod. 77 (2007) 1049-1059
33. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 34 (2006) 241-255
34. Meager A. Biological assays for interferons. J. Immunol. Methods 261 (2002) 21-36
35. Miller C.J., and Shattock R.J. Target cells in vaginal HIV transmission. Microbes Infect. 5 (2003) 59-67
36. Paladino P., Cummings D.T., Noyce R.S., and Mossman K.L. The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J. Immunol. 177 (2006) 8008-8016
37. Paz-Bailey G., Ramaswamy M., Hawkes S.J., and Geretti A.M. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex. Transm. Infect. 83 (2007) 16-22
38. Pyles R.B., Higgins D., Chalk C., Zalar A., Eiden J., Brown C., Van Nest G., and Stanberry L.R. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital Herpes simplex virus type 2 infection. J. Virol. 76 (2002) 11387-11396
39. Sajic D., Ashkar A.A., Patrick A.J., McCluskie M.J., Davis H.L., Levine K.L., Holl R., and Rosenthal K.L. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J. Med. Virol. 71 (2003) 561-568
40. Schaefer T.M., Fahey J.V., Wright J.A., and Wira C.R. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J. Immunol. 174 (2005) 992-1002
41. Simmons A. Clinical manifestations and treatment considerations of Herpes simplex virus infection. J. Infect. Dis. 186 Suppl. 1 (2002) S71-S77
42. Smith J.S., and Robinson N.J. Age-specific prevalence of infection with Herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186 Suppl. 1 (2002) S3-S28
43. van de Wijgert J.H., and Shattock R.J. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 21 (2007) 2369-2376
44. Wira C.R., Grant-Tschudy K.S., and Crane-Godreau M.A. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am. J. Reprod. Immunol 53 (2005) 65-76
45. Yudin M.H., and Kaul R. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy. Infect. Dis. Obstet. Gynecol. 2008 (2008) 592532